RBC Capital analyst Gregory Renza downgraded Morphic (MORF) to Sector Perform from Outperform with a price target of $57, down from $70. The firm views the Eli Lilly (LLY) takeover price as “fair and solid.” With limited antitrust concerns, RBC expects the deal to close in Q3 as guided.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MORF: